99Z:F:F-MODUS THERAPEUTICS HLDG (EUR)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.0864

Change

0.00 (-0.92)%

Market Cap

USD 3.96M

Volume

1.00K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NOVA:F Novo Nordisk A/S

N/A

USD 525.74B
VX1:F Vertex Pharmaceuticals Incorpo..

N/A

USD 96.61B
RGO:F Regeneron Pharmaceuticals Inc

N/A

USD 92.42B
CSJ:F CSL Limited

N/A

USD 83.77B
CSJA:F CSL LTD SPON.ADR 2

N/A

USD 78.61B
0QF:F Moderna Inc

N/A

USD 38.54B
UNC0:F UCB S.A. UNSP.ADR 1/2

N/A

USD 23.00B
UNC:F UCB SA

N/A

USD 22.90B
1AEA:F argenx SE

N/A

USD 20.76B
1AE:F Argen-X

N/A

USD 20.76B

ETFs Containing 99Z:F

DWMC 1.80 % 0.00 %

N/A

N/A
IWC iShares Micro-Cap ETF 1.21 % 0.60 %

N/A

USD 0.89B
ISMD Inspire Small/Mid Cap Imp.. 0.00 % 0.62 %

N/A

USD 0.16B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -40.00% 13% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -40.00% 13% F 5% F
Trailing 12 Months  
Capital Gain -54.04% 24% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -54.04% 24% F 12% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -6.10% 48% F 25% F
Dividend Return -6.10% 48% F 23% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 15.11% 78% C+ 65% D
Risk Adjusted Return -40.38% 42% F 26% F
Market Capitalization 3.96M 10% F 6% D-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.